Federal Register / Vol. 78, No. 119 / Thursday, June 20, 2013 / Notices 37237 

INTERNATIONAL TRADE 

COMMISSION 

[USITC SE–13–015] 

Sunshine Act Meeting Notice 

AGENCY HOLDING THE MEETING: United 

States International Trade Commission. 

TIME AND DATE: June 28, 2013 at 11:00 

a.m. 

PLACE: Room 101, 500 E Street SW., 

Washington, DC 20436, Telephone: 

(202) 205–2000. 

STATUS: Open to the public. 

MATTERS TO BE CONSIDERED: 

1. Agendas for future meetings: None. 

2. Minutes. 

3. Ratification List. 

4. Vote in Inv. Nos. 731–TA–1210–1212 

(Preliminary) (Welded Stainless 

Steel Pressure Pipe from Malaysia, 

Thailand, and Vietnam). The 

Commission is currently scheduled 

to transmit its determinations to the 

Secretary of Commerce on or before 

July 1, 2013; Commissioners’ 

opinions are currently scheduled to 

be transmitted to the Secretary of 

Commerce on or before July 9, 2013. 

5. Outstanding action jackets: None. 

In accordance with Commission 

policy, subject matter listed above, not 

disposed of at the scheduled meeting, 

may be carried over to the agenda of the 

following meeting. 

Issued: June 18, 2013. 

By order of the Commission. 

William R. Bishop, 

Supervisory Hearings and Information 

Officer. 

[FR Doc. 2013–14807 Filed 6–18–13; 11:15 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–365] 

Proposed Adjustments to the 

Aggregate Production Quotas for 

Schedule I and II Controlled 

Substances and Assessment of 

Annual Needs for the List I Chemicals 

Ephedrine, Pseudoephedrine, and 

Phenylpropanolamine for 2013 

AGENCY: Drug Enforcement 

Administration (DEA), Department of 

Justice. 

ACTION: Notice with request for 

comments. 

SUMMARY: This notice proposes to adjust 

the 2013 aggregate production quotas for 

several controlled substances in 

schedules I and II of the Controlled 

Substances Act (CSA) and assessment of 

annual needs for the list I chemicals 

ephedrine, pseudoephedrine, and 

phenylpropanolamine, as well as to 

establish the 2013 aggregate production 

quotas for three recently temporarily 

scheduled substances. 

DATES: Electronic comments must be 

submitted and written comments must 

be postmarked on or before July 22, 

2013. The electronic Federal Docket 

Management System will not accept 

comments after midnight Eastern Time 

on the last day of the comment period. 

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–365’’ on all electronic and 

written correspondence. DEA 

encourages all comments be submitted 

electronically through http:// 

www.regulations.gov using the 

electronic comment form provided on 

that site. An electronic copy of this 

document is also available at http:// 

www.regulations.gov for easy reference. 

Paper comments that duplicate the 

electronic submission are not necessary 

and are strongly discouraged as all 

comments submitted to 

www.regulations.gov will be posted for 

public review and are part of the official 

docket record. Should you, however, 

wish to submit written comments via 

regular or express mail, they should be 

sent to the Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODL, 8701 

Morrissette Drive, Springfield, VA 

22152. 

FOR FURTHER INFORMATION CONTACT: John 

W. Partridge, Executive Assistant, Office 

of Diversion Control, Drug Enforcement 

Administration, 8701 Morrissette Drive, 

Springfield, VA 22152; Telephone: (202) 

307–7165. 

SUPPLEMENTARY INFORMATION: 

Posting of Public Comments 

All comments received are considered 

part of the public record and made 

available for public inspection online at 

http://www.regulations.gov and in the 

DEA’s public docket. Such information 

includes personal identifying 

information (such as your name, 

address, etc.) voluntarily submitted by 

the commenter. 

If you want to submit personal 

identifying information (such as your 

name, address, etc.) as part of your 

comment, but do not want it to be 

posted online or made available in the 

public docket, you must include the 

phrase ‘‘PERSONAL IDENTIFYING 

INFORMATION’’ in the first paragraph 

of your comment. You must also place 

all the personal identifying information 

you do not want posted online or made 

available in the public docket in the first 

paragraph of your comment and identify 

what information you want redacted. 

If you want to submit confidential 

business information as part of your 

comment, but do not want it to be 

posted online or made available in the 

public docket, you must include the 

phrase ‘‘CONFIDENTIAL BUSINESS 

INFORMATION’’ in the first paragraph 

of your comment. You must also 

prominently identify confidential 

business information to be redacted 

within the comment. If a comment has 

so much confidential business 

information that it cannot be effectively 

redacted, all or part of that comment 

may not be posted online or made 

available in the public docket. 

Personal identifying information and 

confidential business information 

identified and located as set forth above 

will be redacted, and the comment, in 

redacted form, will be posted online and 

placed in the DEA’s public docket file. 

Please note that the Freedom of 

Information Act applies to all comments 

received. If you wish to inspect the 

agency’s public docket file in person by 

appointment, please see the FOR

FURTHER INFORMATION CONTACT

paragraph. 

Background 

Section 306 of the CSA (21 U.S.C. 

826) requires the Attorney General to 

establish aggregate production quotas 

for each basic class of controlled 

substance listed in schedules I and II 

and for ephedrine, pseudoephedrine, 

and phenylpropanolamine. This 

responsibility has been delegated to the 

Administrator of the DEA through 28 

CFR 0.100. The Administrator, in turn, 

has redelegated this function to the 

Deputy Administrator, pursuant to 28 

CFR 0.104. DEA published the 2013 

established aggregate production quotas 

for controlled substances in schedules I 

and II and assessment of annual needs 

for the list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine in the Federal 

Register (77 FR 59980) on October 1, 

2012. That notice stipulated that, as 

provided for in 21 CFR 1303.13 and 21 

CFR 1315.13, all aggregate production 

quotas and assessments of annual need 

are subject to adjustment. 

Analysis for Proposed Aggregate 

Production Quotas for Temporarily 

Scheduled Substances 

On May 16, 2013, the Deputy 

Administrator issued a final order to 

temporarily schedule three synthetic 

cannabinoids in schedule I of the CSA: 

(1-Pentyl-1H-indol-3-yl)(2,2,3,3- 

tetramethylcyclopropyl)methanone 


TKELLEY on DSK3SPTVN1PROD with NOTICES
37238 Federal Register / Vol. 78, No. 119 / Thursday, June 20, 2013 / Notices 

(UR–144); [1-(5-fluoro-pentyl)-1H-indol3-yl](2,2,3,3- 

tetramethylcyclopropyl)methanone 

(XLR11); and N-(1-adamantyl)-1-pentyl1H-indazole-3-carboxamide (AKB48). 

See 78 FR 28735. DEA has received 

applications for registration and quota 

for these temporarily scheduled 

substances. In examining the 

information provided by the applicants, 

along with other information, DEA finds 

that there is a current need for these 

substances. Aggregate production quotas 

represent those quantities of schedule I 

and II controlled substances to be 

manufactured in the United States in 

2013 to provide for the estimated 

medical, scientific, research, and 

industrial needs of the United States, 

lawful export requirements, and the 

establishment and maintenance of 

reserve stocks. As such, pursuant to 21 

U.S.C. 826(a), the Deputy Administrator 

must determine the total quantity and 

establish production quotas for each of 

the three temporarily scheduled 

substances. 

In making this determination, the 

Deputy Administrator has taken into 

account the criteria that DEA is required 

to consider in accordance with 21 

U.S.C. 826(a) and 21 CFR 1303.11. DEA 

proposes the aggregate production 

quotas for these three temporarily 

scheduled substances by considering: 

(1) Total estimated net disposal of each 

substance by all manufacturers; (2) 

estimated trends in the national rate of 

net disposal; (3) total estimated 

inventories of the basic class and of all 

substances manufactured from the class; 

(4) projected demand for each class as 

indicated by procurement quotas 

requested pursuant to 21 CFR 1303.12; 

and (5) other factors affecting medical, 

scientific, research, and industrial needs 

of the United States and lawful export 

requirements, as the Deputy 

Administrator finds relevant. These 

quotas do not include imports of 

controlled substances for use in 

industrial processes. 

Analysis for Proposed Revised 2013 

Aggregate Production Quotas and 

Assessment of Annual Needs 

DEA proposes to adjust the 

established 2013 aggregate production 

quotas for some schedule I and II 

controlled substances to be 

manufactured in the United States in 

2013 to provide for the estimated 

medical, scientific, research, and 

industrial needs of the United States, 

lawful export requirements, and the 

establishment and maintenance of 

reserve stocks. These quotas do not 

include imports of controlled 

substances for use in industrial 

processes. DEA is not proposing to 

adjust the assessment of annual needs 

for the list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine at this time. 

In proposing the adjustment, DEA has 

taken into account the criteria that DEA 

is required to consider in accordance 

with 21 CFR 1303.13 and 21 CFR 

1315.13. DEA determines whether to 

propose an adjustment of the aggregate 

production quotas for basic classes of 

schedule I and II controlled substances 

and ephedrine, pseudoephedrine, and 

phenylpropanolamine by considering: 

(1) Changes in demand for the basic 

class, changes in the national rate of net 

disposal for the class, and changes in 

the rate of net disposal by the registrants 

holding individual manufacturing 

quotas for the class; (2) whether any 

increased demand or changes in the 

national or individual rates of net 

disposal are temporary, short term, or 

long term; (3) whether any increased 

demand can be met through existing 

inventories, increased individual 

manufacturing quotas, or increased 

importation, without increasing the 

aggregate production quota; (4) whether 

any decreased demand will result in 

excessive inventory accumulation by all 

persons registered to handle the class; 

and (5) other factors affecting the 

medical, scientific, research, and 

industrial needs of the United States 

and lawful export requirements, as the 

Deputy Administrator finds relevant. 

DEA also considered updated 

information obtained from 2012 yearend inventories, 2012 disposition data 

submitted by quota applicants, 

estimates of the medical needs of the 

United States, product development, 

and other information made available to 

DEA after the initial aggregate 

production quotas and assessment of 

annual needs had been established. 

Other factors DEA considered in 

calculating the aggregate production 

quotas, but not the assessment of annual 

needs, include product development 

requirements of both bulk and finished 

dosage form manufacturers, and other 

pertinent information. In determining 

the proposed revised 2013 assessment of 

annual needs, DEA used the calculation 

methodology previously described in 

the 2010 and 2011 assessment of annual 

needs (74 FR 60294 and 75 FR 79407, 

respectively). 

As described in the previously 

published notice establishing the 2013 

aggregate production quotas and 

assessment of annual needs, DEA has 

specifically considered that inventory 

allowances granted to individual 

manufacturers may not always result in 

the availability of sufficient quantities to 

maintain an adequate reserve stock 

pursuant to 21 U.S.C. 826(a), as 

intended. See 21 CFR 1303.24. This 

would be concerning if a natural 

disaster or other unforeseen event 

resulted in substantial disruption to the 

amount of controlled substances 

available to provide for legitimate 

public need. As such, DEA has included 

in all proposed revised schedule II 

aggregate production quotas, and certain 

schedule I aggregate production quotas, 

an additional 25% of the estimated 

medical, scientific, and research needs 

as part of the amount necessary to 

ensure the establishment and 

maintenance of reserve stocks. The 

resulting revised established aggregate 

production quota will reflect these 

included amounts. This action will not 

affect the ability of manufacturers to 

maintain inventory allowances as 

specified by regulation. DEA expects 

that maintaining this reserve in certain 

established aggregate production quotas 

will mitigate adverse public effects if an 

unforeseen event resulted in substantial 

disruption to the amount of controlled 

substances available to provide for 

legitimate public need, as determined 

by DEA. DEA does not anticipate 

utilizing the reserve in the absence of 

these circumstances. 

The Deputy Administrator, therefore, 

proposes that the year 2013 aggregate 

production quotas for the three 

temporarily scheduled substances be 

established, and to adjust the 2013 

aggregate production quotas for some 

schedule I and II controlled substances 

and ephedrine, pseudoephedrine, and 

phenylpropanolamine, expressed in 

grams of anhydrous acid or base, as 

follows: 


TKELLEY on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 78, No. 119 / Thursday, June 20, 2013 / Notices 37239 

Basic class 

Previously 

established 

2013 quotas 

Proposed or 

proposed 

adjusted 

2013 quotas 

Temporarily Scheduled Substances 

(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR–144) .................................................... N/A 15 g. 

[1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11) ....................................... N/A 15 g. 

N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48) .......................................................................... N/A 15 g. 

Schedule I 

1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) ............................................................................................. 45 g No change. 

1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ............................................................................................ 45 g No change. 

1-[1-(2-Thienyl)cyclohexyl]piperidine .................................................................................................................... 5 g No change. 

1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH–200) ............................................................................... 45 g No change. 

1-Butyl-3-(1-naphthoyl)indole (JWH–073) ............................................................................................................ 45 g No change. 

1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR–18 and RCS–8) .......................................................... 45 g No change. 

1-Hexyl-3-(1-naphthoyl)indole (JWH–019) ........................................................................................................... 45 g No change. 

1-Methyl-4-phenyl-4-propionoxypiperidine ............................................................................................................ 2 g No change. 

1-Pentyl-3-(1-naphthoyl)indole (JWH–018 and AM678) ...................................................................................... 45 g No change. 

1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH–203) ............................................................................................ 45 g No change. 

1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH–250) ........................................................................................ 45 g No change. 

1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH–398) ............................................................................................ 45 g No change. 

1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH–122) ........................................................................................... 45 g No change. 

1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR–19, RCS–4) .................................................................................... 45 g No change. 

1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH–081) ....................................................................................... 45 g No change. 

2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C–P) ................................................................................... 15 g No change. 

2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E) ........................................................................................... 15 g No change. 

2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C–D) ........................................................................................ 15 g No change. 

2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C–N) .......................................................................................... 15 g No change. 

2-(2,5-Dimethoxyphenyl)ethanamine (2C–H) ....................................................................................................... 15 g No change. 

2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C) ......................................................................................... 15 g No change. 

2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I) .............................................................................................. 15 g No change. 

2,5-Dimethoxy-4-ethylamphetamine (DOET) ....................................................................................................... 12 g No change. 

2,5-Dimethoxy-4-n-propylthiophenethylamine ...................................................................................................... 12 g No change. 

2,5-Dimethoxyamphetamine ................................................................................................................................. 12 g No change. 

2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–2) ................................................................................ 15 g No change. 

2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–4) ......................................................................... 15 g No change. 

3,4,5-Trimethoxyamphetamine ............................................................................................................................. 12 g No change. 

3,4-Methylenedioxyamphetamine (MDA) ............................................................................................................. 30 g No change. 

3,4-Methylenedioxymethamphetamine (MDMA) .................................................................................................. 35 g 50 g. 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) .............................................................................................. 24 g No change. 

3,4-Methylenedioxy-N-methylcathinone (methylone) ........................................................................................... 35 g No change. 

3,4-Methylenedioxypyrovalerone (MDPV) ............................................................................................................ 25 g No change. 

3-Methylfentanyl .................................................................................................................................................... 2 g No change. 

3-Methylthiofentanyl .............................................................................................................................................. 2 g No change. 

4-Bromo-2,5-dimethoxyamphetamine (DOB) ....................................................................................................... 12 g No change. 

4-Bromo-2,5-dimethoxyphenethylamine (2–CB) .................................................................................................. 12 g No change. 

4-Methoxyamphetamine ....................................................................................................................................... 88 g No change. 

4-Methyl-2,5-dimethoxyamphetamine (DOM) ....................................................................................................... 12 g 25 g. 

4-Methylaminorex ................................................................................................................................................. 12 g No change. 

4-Methyl-N-methylcathinone (mephedrone) ......................................................................................................... 25 g No change. 

5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol .......................................................................... 68 g No change. 

5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP–47, 497 C8-homolog).53 g No change. 

5-Methoxy-3,4-methylenedioxyamphetamine ....................................................................................................... 12 g No change. 

5-Methoxy-N,N-diisopropyltryptamine ................................................................................................................... 12 g No change. 

5-Methoxy-N,N-dimethyltryptamine ...................................................................................................................... 10 g No change. 

Acetyl-alpha-methylfentanyl .................................................................................................................................. 2 g No change. 

Acetyldihydrocodeine ............................................................................................................................................ 2 g No change. 

Acetylmethadol ..................................................................................................................................................... 2 g No change. 

Allylprodine ........................................................................................................................................................... 2 g No change. 

Alphacetylmethadol ............................................................................................................................................... 2 g No change. 

Alpha-ethyltryptamine ........................................................................................................................................... 12 g No change. 

Alphameprodine .................................................................................................................................................... 2 g No change. 

Alphamethadol ...................................................................................................................................................... 2 g No change. 

Alpha-methylfentanyl ............................................................................................................................................ 2 g No change. 

Alpha-methylthiofentanyl ....................................................................................................................................... 2 g No change. 

Alpha-methyltryptamine (AMT) ............................................................................................................................. 12 g No change. 

Aminorex ............................................................................................................................................................... 12 g No change. 

Benzylmorphine .................................................................................................................................................... 2 g No change. 

Betacetylmethadol ................................................................................................................................................ 2 g No change. 

Beta-hydroxy-3-methylfentanyl ............................................................................................................................. 2 g No change. 

Beta-hydroxyfentanyl ............................................................................................................................................ 2 g No change. 


TKELLEY on DSK3SPTVN1PROD with NOTICES
37240 Federal Register / Vol. 78, No. 119 / Thursday, June 20, 2013 / Notices 

Basic class 

Previously 

established 

2013 quotas 

Proposed or 

proposed 

adjusted 

2013 quotas 

Betameprodine ...................................................................................................................................................... 2 g No change. 

Betamethadol ........................................................................................................................................................ 2 g No change. 

Betaprodine ........................................................................................................................................................... 2 g No change. 

Bufotenine ............................................................................................................................................................. 3 g No change. 

Cathinone .............................................................................................................................................................. 12 g No change. 

Codeine-N-oxide ................................................................................................................................................... 602 g No change. 

Desomorphine ....................................................................................................................................................... 5 g No change. 

Diethyltryptamine .................................................................................................................................................. 12 g No change. 

Difenoxin ............................................................................................................................................................... 50 g No change. 

Dihydromorphine ................................................................................................................................................... 3,300,000 g No change. 

Dimethyltryptamine ............................................................................................................................................... 18 g No change. 

Gamma-hydroxybutyric acid ................................................................................................................................. 46,250,000 g No change. 

Heroin ................................................................................................................................................................... 25 g No change. 

Hydromorphinol ..................................................................................................................................................... 54 g No change. 

Hydroxypethidine .................................................................................................................................................. 2 g No change. 

Ibogaine ................................................................................................................................................................ 5 g No change. 

Lysergic acid diethylamide (LSD) ......................................................................................................................... 30 g No change. 

Marihuana ............................................................................................................................................................. 21,000 g No change. 

Mescaline .............................................................................................................................................................. 13 g No change. 

Methaqualone ....................................................................................................................................................... 10 g No change. 

Methcathinone ...................................................................................................................................................... 14 g No change. 

Methyldihydromorphine ......................................................................................................................................... 2 g No change. 

Morphine-N-oxide ................................................................................................................................................. 655 g No change. 

N,N-Dimethylamphetamine ................................................................................................................................... 12 g No change. 

N-Benzylpiperazine ............................................................................................................................................... 15 g No change. 

N-Ethylamphetamine ............................................................................................................................................ 12 g No change. 

N-Hydroxy-3,4-methylenedioxyamphetamine ....................................................................................................... 12 g No change. 

Noracymethadol .................................................................................................................................................... 2 g No change. 

Norlevorphanol ...................................................................................................................................................... 52 g No change. 

Normethadone ...................................................................................................................................................... 2 g No change. 

Normorphine ......................................................................................................................................................... 18 g No change. 

Para-fluorofentanyl ................................................................................................................................................ 2 g No change. 

Phenomorphan ..................................................................................................................................................... 2 g No change. 

Pholcodine ............................................................................................................................................................ 2 g No change. 

Properidine ............................................................................................................................................................ 2 g No change. 

Psilocybin .............................................................................................................................................................. 2 g 10 g. 

Psilocyn ................................................................................................................................................................. 4 g No change. 

Tetrahydrocannabinols ......................................................................................................................................... 491,000 g No change. 

Thiofentanyl .......................................................................................................................................................... 2 g No change. 

Tilidine ................................................................................................................................................................... 10 g No change. 

Trimeperidine ........................................................................................................................................................ 2 g No change. 

Schedule II 

1-Phenylcyclohexylamine ..................................................................................................................................... 3 g No change. 

1-Piperdinocyclohexanecarbonitrile ...................................................................................................................... 21 g No change. 

4-Anilino-N-phenethyl-4-piperidine (ANPP) .......................................................................................................... 2,250,000 g No change. 

Alfentanil ............................................................................................................................................................... 38,250 g No change. 

Alphaprodine ......................................................................................................................................................... 3 g No change. 

Amobarbital ........................................................................................................................................................... 9 g No change. 

Amphetamine (for conversion) ............................................................................................................................. 22,875,000 g No change. 

Amphetamine (for sale) ........................................................................................................................................ 42,625,000 g 47,186,000 g. 

Carfentanil ............................................................................................................................................................. 6 g No change. 

Cocaine ................................................................................................................................................................. 240,000 g No change. 

Codeine (for conversion) ...................................................................................................................................... 81,250,000 g No change. 

Codeine (for sale) ................................................................................................................................................. 49,506,250 g No change. 

Dextropropoxyphene ............................................................................................................................................. 19 g No change. 

Dihydrocodeine ..................................................................................................................................................... 250,000 g No change. 

Diphenoxylate ....................................................................................................................................................... 750,000 g No change. 

Ecgonine ............................................................................................................................................................... 127,500 g 144,000 g. 

Ethylmorphine ....................................................................................................................................................... 3 g No change. 

Fentanyl ................................................................................................................................................................ 2,108,750 g No change. 

Glutethimide .......................................................................................................................................................... 3 g No change. 

Hydrocodone (for sale) ......................................................................................................................................... 99,625,000 g No change. 

Hydromorphone .................................................................................................................................................... 5,968,750 g No change. 

Isomethadone ....................................................................................................................................................... 5 g No change. 

Levo-alphacetylmethadol (LAAM) ......................................................................................................................... 4 g No change. 

Levomethorphan ................................................................................................................................................... 6 g No change. 

Levorphanol .......................................................................................................................................................... 4,500 g No change. 

Lisdexamfetamine ................................................................................................................................................. 21,000,000 g No change. 

Meperidine ............................................................................................................................................................ 6,875,000 g No change. 


TKELLEY on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 78, No. 119 / Thursday, June 20, 2013 / Notices 37241 

Basic class 

Previously 

established 

2013 quotas 

Proposed or 

proposed 

adjusted 

2013 quotas 

Meperidine Intermediate—A ................................................................................................................................. 6 g No change. 

Meperidine Intermediate—B ................................................................................................................................. 11 g No change. 

Meperidine Intermediate—C ................................................................................................................................. 6 g No change. 

Metazocine ............................................................................................................................................................ 6 g No change. 

Methadone (for sale) ............................................................................................................................................ 25,000,000 g 33,125,000 g. 

Methadone Intermediate ....................................................................................................................................... 32,500,000 g 40,500,000 g. 

Methamphetamine ................................................................................................................................................ 3,912,500 g No change. 

[987,500 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,863,750 grams for methamphetamine mostly 

for conversion to a schedule III product; and 61,250 grams for methamphetamine (for sale)] 

Methylphenidate .................................................................................................................................................... 80,750,000 g 96,750,000 g. 

Morphine (for conversion) ..................................................................................................................................... 103,750,000 g 91,250,000 g. 

Morphine (for sale) ............................................................................................................................................... 60,250,000 g No change. 

Nabilone ................................................................................................................................................................ 25,628 g No change. 

Noroxymorphone (for conversion) ........................................................................................................................ 9,000,000 g No change. 

Noroxymorphone (for sale) ................................................................................................................................... 508,750 g 1,262,500 g. 

Opium (powder) .................................................................................................................................................... 91,250 g No change. 

Opium (tincture) .................................................................................................................................................... 1,287,500 g No change. 

Oripavine ............................................................................................................................................................... 22,750,000 g No change. 

Oxycodone (for conversion) ................................................................................................................................. 10,250,000 g No change. 

Oxycodone (for sale) ............................................................................................................................................ 131,500,000 g 153,750,000 g. 

Oxymorphone (for conversion) ............................................................................................................................. 18,375,000 g No change. 

Oxymorphone (for sale) ........................................................................................................................................ 6,875,000 g No change. 

Pentobarbital ......................................................................................................................................................... 42,500,000 g No change. 

Phenazocine ......................................................................................................................................................... 6 g No change. 

Phencyclidine ........................................................................................................................................................ 30 g No change. 

Phenmetrazine ...................................................................................................................................................... 3 g No change. 

Phenylacetone ...................................................................................................................................................... 20,000,000 g 29,628,750 g. 

Racemethorphan .................................................................................................................................................. 3 g No change. 

Remifentanil .......................................................................................................................................................... 3,750 g No change. 

Secobarbital .......................................................................................................................................................... 215,003 g No change. 

Sufentanil .............................................................................................................................................................. 6,255 g No change. 

Tapentadol ............................................................................................................................................................ 13,750,000 g No change. 

Thebaine ............................................................................................................................................................... 145,000,000 g No change. 

List I Chemicals 

Ephedrine (for conversion) ................................................................................................................................... 15,100,000 g No change. 

Ephedrine (for sale) .............................................................................................................................................. 3,500,000 g No change. 

Phenylpropanolamine (for conversion) ................................................................................................................. 25,700,000 g No change. 

Phenylpropanolamine (for sale) ............................................................................................................................ 6,100,000 g No change. 

Pseudoephedrine (for sale) .................................................................................................................................. 225,000,000 g No change. 

The Deputy Administrator further 

proposes that aggregate production 

quotas for all other schedule I and II 

controlled substances included in 21 

CFR 1308.11 and 1308.12 remain at 

zero. Pursuant to 21 CFR 1303.13 and 21 

CFR 1315.13, upon consideration of the 

relevant factors, the Deputy 

Administrator may adjust the 2013 

aggregate production quotas and 

assessment of annual needs as needed. 

Comments 

Pursuant to 21 CFR 1303.11 and 21 

CFR 1315.11, any interested person may 

submit written comments on or 

objections to these proposed 

determinations. Based on comments 

received in response to this Notice, the 

Deputy Administrator may hold a 

public hearing on one or more issues 

raised. In the event the Deputy 

Administrator decides in his sole 

discretion to hold such a hearing, the 

Deputy Administrator will publish a 

notice of any such hearing in the 

Federal Register. After consideration of 

any comments and after a hearing, if one 

is held, the Deputy Administrator will 

publish in the Federal Register a Final 

Order establishing any adjustment of 

2013 aggregate production quota for 

each basic class of controlled substance 

and assessment of annual needs for the 

list I chemicals ephedrine, 

pseudoephedrine, and 

phenylpropanolamine. 

Dated: June 14, 2013. 

Thomas M. Harrigan, 

Deputy Administrator. 

[FR Doc. 2013–14723 Filed 6–19–13; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application; 

Noramco, Inc. (GA) 

Pursuant to § 1301.33(a), Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on March 21, 2012, 

Noramco, Inc., 1440 Olympic Drive, 

Athens, Georgia 30601, made 

application to the Drug Enforcement 

Administration (DEA) to be registered as 

a bulk manufacturer of Opium tincture 

(9630), a basic class of controlled 

substance listed in schedule II. 

The company plans to manufacture 

the listed controlled substance in bulk 

for distribution to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substance, 


TKELLEY on DSK3SPTVN1PROD with NOTICES